Comera Life Sciences Holdings, Inc.
CMRA
$0.00
$0.000.00%
OTC PK
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Revenue | 136.30K | 315.10K | 392.90K | 156.10K | 234.90K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 136.30K | 315.10K | 392.90K | 156.10K | 234.90K |
| Cost of Revenue | 42.00K | 56.00K | 116.50K | 50.40K | 61.00K |
| Gross Profit | 94.30K | 259.00K | 276.40K | 105.80K | 174.00K |
| SG&A Expenses | 1.89M | 1.55M | 2.43M | 1.17M | 2.31M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.29M | 1.80M | 2.89M | 1.67M | 2.77M |
| Operating Income | -2.16M | -1.48M | -2.50M | -1.51M | -2.54M |
| Income Before Tax | -2.15M | -1.41M | -2.48M | -2.96M | -3.08M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -2.15M | -1.41M | -2.48M | -2.96M | -3.08M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.15M | -1.41M | -2.48M | -2.96M | -3.08M |
| EBIT | -2.16M | -1.48M | -2.50M | -1.51M | -2.54M |
| EBITDA | -2.13M | -1.46M | -2.47M | -1.49M | -2.51M |
| EPS Basic | -0.10 | -0.08 | -0.13 | -0.18 | -0.20 |
| Normalized Basic EPS | -0.06 | -0.05 | -0.08 | -0.05 | -0.12 |
| EPS Diluted | -0.10 | -0.08 | -0.13 | -0.18 | -0.20 |
| Normalized Diluted EPS | -0.06 | -0.05 | -0.08 | -0.05 | -0.12 |
| Average Basic Shares Outstanding | 23.11M | 19.15M | 19.03M | 16.69M | 16.02M |
| Average Diluted Shares Outstanding | 23.11M | 19.15M | 19.03M | 16.69M | 16.02M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |